Decrease in Prosaposin in the Dystrophic mdx Mouse Brain

Hui-ling Gao1,4, Cheng Li1,5, Hiroaki Nabeka1*, Tetsuya Shimokawa1, Naoto Kobayashi2, Shouichiro Saito3, Zhan-You Wang4, Ya-ming Cao5, Seiji Matsuda1

1 Department of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 2 Medical Education Center, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 3 Laboratory of Veterinary Anatomy, Faculty of Applied Biological Sciences, Gifu University, Yanagido, Gifu, Japan, 4 College of Life and Health Sciences, Northeastern University, Shenyang, China, 5 Department of Immunology, China Medical University, Shenyang, China

Abstract

Background: Duchenne muscular dystrophy caused by a mutation in the X-linked dystrophin gene induces metabolic and structural disorders in the brain. A lack of dystrophin in brain structures is involved in impaired cognitive function. Prosaposin (PS), a neurotrophic factor, is abundant in the choroid plexus and various brain regions. We investigated whether PS serves as a link between dystrophin loss and gross and/or ultrastructural brain abnormalities.

Methodology/Principal Findings: The distribution of PS in the brains of juvenile and adult mdx mice was investigated by immunochemistry, Western blotting, and in situ hybridization. Immunochemistry revealed lower levels of PS in the cytoplasm of neurons of the cerebral cortex, hippocampus, cerebellum, and choroid plexus in mdx mice. Western blotting confirmed that PS levels were lower in these brain regions in both juveniles and adults. Even with low PS production in the choroids plexus, there was no significant PS decrease in cerebrospinal fluid (CSF). In situ hybridization revealed that the primary form of PS mRNA in both normal and mdx mice was Pro+9, a secretory-type PS, and the hybridization signals for Pro+9 in the above-mentioned brain regions were weaker in mdx mice than in normal mice. We also investigated mitogen-activated protein kinase signalling. Stronger activation of ERK1/2 was observed in mdx mice, ERK1/2 activity was positively correlated with PS activity, and exogenous PS18 stimulated both p-ERK1/2 and PS in SH-SY5Y cells.

Conclusions/Significance: Low levels of PS and its receptors suggest the participation of PS in some pathological changes in the brains of mdx mice.

Citation: Gao H-l, Li C, Nabeka H, Shimokawa T, Kobayashi N, et al. (2013) Decrease in Prosaposin in the Dystrophic mdx Mouse Brain. PLoS ONE 8(11): e80032. doi:10.1371/journal.pone.0080032

Introduction

Prosaposin (PS) is a multifunctional protein involved in a variety of biological processes, where it is either transported to lysosomes or secreted into the extracellular space [1-3]. In lysosomes, PS is proteolytically processed to generate four sphingolipid activator proteins, known as saposins A to D, which are required for hydrolysis of sphingolipids by several lysosomal exohydrolases. Many functions have been attributed to secreted PS, which is reportedly a trophic factor in the nervous and reproductive systems, being present in milk and cerebrospinal and seminal fluids [4-8].

The PS gene contains 15 exons. It is transcribed into several mRNAs, resulting from alternative splicing of the 9-bp exon 8 [9]. In situ hybridization has shown abundant PS expression in the epithelial cells of the choroid plexus and various grey matter areas, including the cortex and hippocampus [10,11]. Besides its role as the precursor protein of saposins, PS is also a neurotrophic factor [12] capable of inducing neural differentiation and preventing cell death. A neurotrophic sequence has been identified in 14 amino acids located in the N-terminal part of saposin C [13] and has been attributed to PS neurotrophic activity [14,15]. Moreover, a PS-derived 18-mer peptide attenuates dopaminergic neurotoxicity by...
downregulating c-Jun, BAX, and caspase-3, and upregulating Bcl-2 [4].

Duchenne muscular dystrophy (DMD) is a fatal genetic disease caused by mutations in the DMD gene, leading to dystrophin deficiency [16,17]. DMD is caused by a mutation in the X-linked dystrophin gene [18]; it is a recessive genetic disease characterised by alterations in the neuromuscular system, and metabolic and structural disorders of the central nervous system (CNS), which cause mental retardation and metabolic damage [19]. While muscle wasting is prominent, the CNS is also affected in DMD, with non-progressive intellectual and/or cognitive impairment being observed in about one-third of patients with DMD [20-22].

The dystrophin-deficient mdx mouse is a model of human DMD [23]. In the brain, the cerebral cortex, cerebellum and areas CA1-CA3 of the hippocampus are regions in which dystrophin is known to be expressed [24-26]. Brain dystrophin is enriched in the postsynaptic densities of pyramidal neurons, specialised regions of the subsynaptic cytoskeletal network that are critical for synaptic transmission and plasticity. Loss of dystrophin, together with a consequent abnormality of the dystrophin-associated protein complex (DAPC), gives rise to a complex syndrome of progressive skeletal and cardiac myopathy and mental retardation. Recently, we reported low levels of PS in muscles in mdx mice compared with C57BL/10 mice [7].

Whether PS is a link between dystrophin loss and gross and/or ultrastructural brain abnormalities remains unclear. In this study, we examined the expression of PS at the protein and transcriptional levels in the CNS of mdx mouse by immunochemistry, Western blotting and in situ hybridization.

Results

PS protein expression in mdx and C57BL/10 mice

To investigate PS protein expression in the mouse cerebral cortex, hippocampus and cerebellum, immunohistochemical and Western blot analyses were performed. PS-like immunoreactivity was observed in different brain regions in juvenile and adult mice. The PS staining exhibited a granular pattern in the cytoplasm of neurons (Figures 1a–d, 2a–l, 3a–d).

Western blot analysis was performed to investigate PS protein expression in mdx and C57BL/10 mice aged 4 and 12 weeks. Since the anti-PS antibody was obtained from the intermediate sequence between saposin C and D, it only reacts with PS and not with saposins in immunochemistry and Western blotting. As expected, PS protein was detected as a band of 65 kDa (Figures 1e, 2m, 3e).

In the cerebral cortex of C57BL/10 mice, PS immunoreactivity was predominantly present in the somas and primary dendrites of most neurons in animals aged 4 and 12 weeks (Figure 1a–d). In the mdx mice, the PS staining pattern was similar, but the staining in the cortex was weaker in mdx mice aged 4 and 12 weeks (Figure 1b, d). This was confirmed by Western blotting (Figure 1e). Densitometric analysis of PS-immunoreactive bands showed that PS levels in the cerebral cortex were significantly lower in mdx mice than in control mice at 4 weeks (0.56 ± 0.09 vs. 0.66 ± 0.11, p < 0.01; Figure 1f) and 12 weeks (0.63 ± 0.10 vs. 0.75 ± 0.11, p < 0.01; Figure 1f).

In the CA1, CA3 and DG areas of the hippocampus, PS grains were primarily observed in the cytoplasm (Figure 2a–l) and in some big neurites extending from PS-positive neuronal somata in the CA1 and CA3 areas (Figure 2a, b, d, e, g, h, j, k).
in C57BL/10 and mdx mice aged 4 and 12 weeks. PS immunoreactivity was weaker in mdx mice than in C57BL/10 mice. In the hippocampus, PS expression was lower in mdx mice than in C57BL/10 mice at both 4 weeks (0.39 ± 0.03 vs.

Figure 2. PS in the hippocampus of C57BL/10 and mdx mice, as detected by immunchemistry and Western blotting. a–l: In the CA1, CA3 and DG areas of the hippocampus, PS immunoreactivity was found in the somas and primary dendrites in both juvenile (a–f) and adult (g–l) C57BL/10 and mdx mice. Bars = 20 μm. m: Western blot analysis showing PS as a 65-kDa protein in the hippocampus of juvenile and adult C57BL/10 and mdx mice. n: Relative protein levels, as determined by densitometry. Densitometric values were normalized using GAPDH as an internal control. Results were analyzed using Fisher’s post hoc test (**p < 0.01).

doi: 10.1371/journal.pone.0080032.g002

Figure 3. PS in the cerebellum of C57BL/10 and mdx mice, as detected by immunchemistry and Western blotting. a–d: Light micrographs showing PS immunoreactivity in Purkinje and granule cell bodies in juvenile (a, b) and adult (c, d) C57BL/10 and mdx mice. M, molecular layer; P, Purkinje cell layer; G, granule cell layer. Bars = 20 μm. e: Western blot analysis showing PS as a 65-kDa protein in the cerebellum of juvenile and adult C57BL/10 and mdx mice. Densitometric analysis showed that PS levels were substantially lower in mdx mice than in control mice both at 4 and 12 weeks (f). The results were analyzed by Fisher’s post hoc test (*p < 0.01).

doi: 10.1371/journal.pone.0080032.g003
0.50 ± 0.02, p < 0.05) and 12 weeks (0.50 ± 0.09 vs. 0.58 ± 0.08, p < 0.05; Figure 2m, n).

In the cerebellum, PS immunoreactivity was predominantly observed in the somas of Purkinje neurons. A few PS-positive neuronal somas were seen in the molecular layer. In the granule cell layer, PS immunoreactivity was observed in the cytoplasm of granule cells (Figure 3a–d). In mdx mice, PS immunoreactivity was much weaker in the Purkinje cell layer and granule cell layer, but not in the molecular layer, compared with control mice. Similar results were obtained by Western blotting. PS levels were significantly lower in mdx mice than in control mice at 4 weeks (0.65 ± 0.09 vs. 0.79 ± 0.10, p < 0.01) and 12 weeks (0.70 ± 0.09 vs. 0.85 ± 0.11, p < 0.01; Figure 3e, f).

PS mRNA expression in mdx and C57BL/10 mice

To determine the spatial expression pattern of PS isoforms at the single-cell level, we analyzed brain sections from juvenile mice (age 4 weeks) by in situ hybridization with [35S]-labelled antisense oligonucleotide probes. b, f: Detection of total mRNA with AS1. c, g: Detection of exon 8-containing PS mRNA with AS3. d, h: Detection of exon 8-excluded PS mRNA with AS4. a, e: the sense probe SS1 (used as a control). Positive reactions (labelled with concentrated silver grains) can be identified in the neurons of control and mdx mice. The hybridization signals for total mRNA (AS1) and Pro+9 mRNA (AS3) were weaker in mdx mice than in C57BL/10 mice. No obvious reactivity was observed for AS4 and SS1. Results were analyzed by ANOVA followed by Fisher’s post hoc test (* p < 0.05). Bars = 10 μm.

doi: 10.1371/journal.pone.0080032.g004

Prosaposin Expression in mdx Mouse Brain

Figure 4. PS mRNA expression in the cerebral cortex of C57BL/10 and mdx mice at 4 weeks, as shown by in situ hybridization with [35S]-labelled antisense oligonucleotide probes. b, f: Detection of total mRNA with AS1. c, g: Detection of exon 8-containing PS mRNA with AS3. d, h: Detection of exon 8-excluded PS mRNA with AS4. a, e: the sense probe SS1 (used as a control). Positive reactions (labelled with concentrated silver grains) can be identified in the neurons of control and mdx mice. The hybridization signals for total mRNA (AS1) and Pro+9 mRNA (AS3) were weaker in mdx mice than in C57BL/10 mice. No obvious reactivity was observed for AS4 and SS1. Results were analyzed by ANOVA followed by Fisher’s post hoc test (* p < 0.05). Bars = 10 μm.

doi: 10.1371/journal.pone.0080032.g004

neurons were observed in various brain regions, including the cerebral cortex, hippocampus and cerebellum, in both mdx and normal mice. To determine whether PS mRNA expression was different between mdx and C57BL/10 mice, we measured the intensities of hybridization signals in brain sections using ImageJ software, and analyzed the data by Fisher’s post hoc test (Figures 4i, 5m–o, 6i–k). In the sections labelled with one of the four probes, the signals showed different intensities. The control group, labelled with the sense probe SS1 showed weak signals (Figure 4a, e). The intensities of the hybridization signals for Pro+0 (AS4) were also weaker (Figure 4d, h). In the cerebral cortex, the hybridization signals for total mRNA (AS1, Pro+9 and Pro+0) for mdx mice (1.23 ± 0.17) were weaker than those for C57BL/10 mice (1.54 ± 0.26; Figure 4b, f, i). The hybridization signal for Pro+9 mRNA (AS3, encoding secretory-type PS) was also weaker in mdx mice than in C57BL/10 mice (1.13 ± 0.17 vs. 1.56 ± 0.20; Figure 4c, g, i). Statistically significant decreases in total and Pro+9 signals were detected in mdx mice (Figure 4i), indicating that the decrease in PS levels in mdx mice is mainly due to a decrease in Pro+9 mRNA expression.
Also in the hippocampal CA1, CA3 and DG areas in mdx and C57BL/10 mice, AS1 (Pro+9 and Pro+0) and AS3 (Pro+9) showed strong signals compared with SS1 (control) and AS4 (Pro+0; Figure 5). In CA1, the intensity of AS1 was significantly lower in mdx mice than in C57BL/10 mice (1.32 ± 0.09 vs. 1.62 ± 0.12, \( p < 0.01 \); Figure 5b1, b2, m). Moreover, the distribution pattern of AS3 in mdx mice was similar to that of AS1, and its intensity was lower in mdx mice compared with C57BL/10 mice (1.45 ± 0.07 vs. 1.90 ± 0.10, \( p < 0.01 \); Figure 5c1, c2, m). In CA3, AS1 was lower in mdx mice compared with C57BL/10 mice (1.51 ± 0.17 vs. 2.01 ± 0.13, \( p < 0.05 \); Figure 5f1, f2, n) and AS3 was also lower in mdx mice than in C57BL/10 mice (1.56 ± 0.16 vs. 1.98 ± 0.13, \( p < 0.05 \); Figure 5g1, g2, n). In DG areas, AS1 and AS3 were also lower in mdx mice than in C57BL/10 mice (AS1: 1.79 ± 0.07 vs. 2.29 ± 0.13, \( p < 0.01 \); Figure 5j1, j2; AS3: 1.75 ± 0.04 vs. 2.43 ± 0.03, \( p < 0.01 \); Figure 5k1, k2, o). AS4 (Pro+0) showed very weak reactions (Figure 5d1, d2, h1, h2, l1, l2), similar to those of the control group labelled with SS1 (Figure 5a1, a2, e1, e2, i1, i2).

In the Purkinje cell layer of the cerebellum, the total PS mRNA (AS1: Pro+9 and Pro+0) and AS3 (Pro+9) signals were lower in mdx mice than in C57BL/10 mice (AS1: 1.79 ± 0.07 vs. 2.29 ± 0.13, \( p < 0.01 \); Figure 5f1, f2, j1, j2); AS3 (Pro+9) and DG were weaker in mdx mice than in C57BL/10 mice (b1, b2, f1, f2, j1, j2). Pro+9 mRNA expression in the hippocampal regions CA1 (c1, c2), CA3 (g1, g2) and DG (k1, k2) decreased in mdx mice. The intensity of the hybridization signal for Pro+0 was weak. The control group labelled with the sense probe SS1 showed no specific signals. m, n, o: Results were analyzed by ANOVA followed by Fisher’s post hoc test (*\( p < 0.05 \), **\( p < 0.01 \)). Bars = 10 μm.

doi: 10.1371/journal.pone.0080032.g005

**Figure 5.** PS mRNA expression in the hippocampal regions of C57BL/10 and mdx mice at 4 weeks. a1-d2: CA1. e1-h2: CA3. i1-l2: Dentate gyrus (DG). Total PS mRNA expression was detected by *in situ* hybridization using AS1, and the signals in the hippocampal regions CA1, CA3 and DG were weaker in mdx mice than in C57BL/10 mice (b1, b2, f1, f2, j1, j2). Pro+9 mRNA expression in the hippocampal regions CA1 (c1, c2), CA3 (g1, g2) and DG (k1, k2) decreased in mdx mice. The intensity of the hybridization signal for Pro+0 was weak. The control group labelled with the sense probe SS1 showed no specific signals. m, n, o: Results were analyzed by ANOVA followed by Fisher’s post hoc test (*\( p < 0.05 \), **\( p < 0.01 \)). Bars = 10 μm.

MAP kinase activity in mdx and C57BL/10 mice

Activation of the MAPK pathway by PS, saposin C or TX14A has been reported in neuronal- or glial-derived cells such as PC12, Schwann and neuroblastaoma cells [27,28]. To determine whether MAPK signalling is related to PS in mdx neurons, we analyzed three components (p38 MAP kinase, ERK1/2 and JNK1/2) of the MAP kinase cascades by Western blotting. ERK1 and ERK2 were dually phosphorylated at T202/Y204 and T185/Y187, respectively, and were detected as double bands at 44 kDa (p-ERK1) and 42 kDa (p-ERK2). Western blotting showed that the level of p-ERK1/2 in the brain was...
higher in mdx mice (ages 4 and 12 weeks) than in C57BL/10 mice of the same age (Figure 7a–c). No differences in the phosphorylation levels of p-JNK1/2 or p38 MAPK (p-p38) were observed between juvenile/adult mdx mice and C57BL/10 mice of the same age (Figure 7a–c). No changes in the core levels (non-phosphorylated forms) of these proteins were detected.

All of the data obtained by Western blotting are summarised as histograms in Figure 8. In the cortex, the level of p-ERK1 increased about 1.1-fold in juvenile mdx mice and about 1.2-fold in adult mdx mice compared with C57BL/10 mice of the same age. The p-ERK2 level increased about 1.05- and 1.08-fold in juvenile and adult mdx mice, respectively, compared with C57BL/10 mice of the same age (Figure 8a). In the hippocampus, the level of p-ERK1 increased about 1.22-fold in juvenile mdx mice and about 1.16-fold in adult mdx mice compared with C57BL/10 mice of the same age (Figure 8b). The p-ERK2 level increased about 1.22- and 1.06-fold in juvenile and adult mdx mice, respectively, compared with C57BL/10 mice of the same age. In the cerebellum, the level of p-ERK1 increased about 1.36- and 1.1-fold in juvenile and adult mdx mice, respectively, compared with C57BL/10 mice of the same age (Figure 8c); the p-ERK2 level increased about 1.04- and 1.08-fold in juvenile and adult of mdx mice, respectively, compared with C57BL/10 mice of the same age (Figure 8c). The level of p-ERK1 and p-ERK2 was also analyzed in the choroid plexus. The p-ERK1 level increased 1.22-fold in juvenile mdx mice and 1.16-fold in adult mdx mice compared to C57BL/10 mice of the same age, while the p-ERK2 level increased 1.32- and 1.33-fold in juvenile and adult mdx mice, respectively, compared to C57BL/10 mice of the same age (Figure 9n-o).
Secreted PS levels in mdx and C57BL/10 mice

Most CSF is produced in the brain by modified ependymal cells in the choroid plexus and the remainder is formed around blood vessels and along ventricular walls. PS exists as a secretory protein in CSF and its expression is concentrated in epithelial cells of the choroid plexus [1,8,29]. To investigate the secreted levels of PS in our study, PS expression in the choroid plexus and CSF were analyzed by immunohistochemistry, Western blotting, and in situ hybridization.

In the choroid plexus of C57BL/10 mice, PS immunoreactivity was predominantly present in the somas ependymal cells in animals aged 4 and 12 weeks (Figure 9a–d). The PS staining pattern was similar but less intense in mdx mice of both ages (Figure 9b, d). This was confirmed by in situ hybridization (Figure 9e–h). The hybridization signals for total mRNA (AS1, Pro+9 and Pro+0) were weaker in mdx mice than in C57BL/10 mice (1.02 ± 0.09 vs. 1.27 ± 0.23; Figure 9i).

Figure 7. MAP kinases in mdx and C57BL/10 mice aged 4 and 12 weeks. a: Cerebral cortex. b: Hippocampus. c: Cerebellum. Three components (p38 MAP kinase, ERK1/2 and JNK1/2) of MAP kinase cascades were analyzed by Western blotting. GAPDH was used as a control for protein loading.

doi: 10.1371/journal.pone.0080032.g007

Figure 8. OD data for MAP kinases in the cerebral cortex, hippocampus and cerebellum in mdx and C57BL/10 mice aged 4 and 12 weeks. Data were shown as the ratio of phosphorylated and non-phosphorylated kinase levels. Levels of p-ERK1/2 in all areas were higher in mdx mice than in C57BL/10 mice at both 4 and 12 weeks (a–c). No differences in the phosphorylation levels of JNK1 or JNK2 between mdx and C57BL/10 mice were observed (d–f). The level of phosphorylated p38 MAPK (p-p38) also showed no difference between mdx and C57BL/10 mice (g–i). All values are the mean ± SD. *p < 0.05, **p < 0.01.

doi: 10.1371/journal.pone.0080032.g008

Prosaposin Expression in mdx Mouse Brain
same was true for Pro+9 mRNA (AS3, encoding secretory-type PS; 1.95 ± 0.16 vs. 2.48 ± 0.19; Figure 9h).

Densitometry of PS-immunoreactive bands showed that PS levels were significantly lower in the choroid plexus of mdx mice than control mice at 4 weeks (0.34 ± 0.04 vs. 0.53 ± 0.15, p < 0.05) and 12 weeks (0.29 ± 0.08 vs. 0.39 ± 0.11, p < 0.05; Figure 9g-k). However, there were no differences in the PS level in CSF between mdx mice and C57BL/10 mice of either age (Figure 9l-m).

GPR37 and GPR37L1 expressions in mdx and C57BL/10 mice

A recent report identified PS and prosaptide as ligands for the orphan receptors GPR37 and GPR37L1 [30] and showed that GPR37 and GPR37L1 mediate protective actions of secreted PS. In our study, the expression of these receptors was detected in the cortex, hippocampus, cerebellum, and choroid plexus of mdx and C57BL/10 mice by Western blot (Figure 10a-b, e-f). Densitometry of immunoreactive bands showed stronger signals for GPR37L1 than GPR37 in brain tissues (Figure 10a-b, e-f). In the cerebral cortex, GPR37 expression was significantly lower in mdx mice than in control mice at 4 weeks (0.59 ± 0.06 vs. 0.76 ± 0.05, p < 0.05; Figure 10c) and 12 weeks (0.45 ± 0.11 vs. 0.66 ± 0.02, p < 0.05; Figure 10c), as was GPR37L1 expression at 4 weeks (1.19 ± 0.09 vs. 1.35 ± 0.10, p < 0.05; Figure 10c) and 12 weeks (0.96 ± 0.04 vs. 1.24 ± 0.09, p < 0.05; Figure 10c). In the hippocampus, GPR37 expression was lower in mdx mice than in C57BL/10 mice at both 4 weeks (0.5 ± 0.07 vs. 0.72 ± 0.03, p < 0.05; Figure 10d) and 12 weeks (0.43 ± 0.04 vs. 0.56 ± 0.12, p < 0.05; Figure 10d). GPR37L1 expression was significantly lower in mdx mice than in control mice at 4 weeks (1.08 ± 0.04 vs. 1.24 ± 0.08, p < 0.05; Figure 10d) and 12 weeks (0.94 ± 0.03 vs. 1.12 ± 0.19, p < 0.05; Figure 10d). Similar results were obtained in the cerebellum. GPR37 expression was lower in mdx mice than in C57BL/10 mice at both 4 weeks (0.41 ± 0.08 vs. 0.53 ± 0.06, p < 0.05; Figure 10g) and 12 weeks (0.44 ± 0.04 vs. 0.54 ± 0.08, p < 0.05; Figure 10g), and GPR37L1 expression was significantly lower in mdx mice than in control mice at 4 weeks (0.75 ± 0.06 vs. 0.92 ±
Figure 10. GPR37 and GPR37L1 expression in mdx and C57BL/10 mice aged 4 and 12 weeks. a: Cerebral cortex. b: Hippocampus. c: Cerebellum. d: Choroid plexus. GPR37 and GPR37L1 were analyzed by Western blotting. GAPDH was used as a control for protein loading. c-d, e-f: Optical density data for GPR37 and GPR37L1 showed that the signal for GPR37L1 is stronger than GPR37 in brain tissues. GPR37 and GPR37L1 were significantly lower in cortex, hippocampus, cerebellum and choroid plexus of mdx mice than those of control mice at 4 weeks and 12 weeks. All values represent means ± SD. *p < 0.05.

doi: 10.1371/journal.pone.0080032.g010

0.11, p < 0.05; Figure 10g) and 12 weeks (0.78 ± 0.07 vs. 0.99 ± 0.15, p < 0.05; Figure 10g). In the choroid plexus, the expressions of GPR37 and GPR37L1 were both lower in mdx mice than in control mice at 4 weeks (GPR37: 0.86 ± 0.03 vs. 1.08 ± 0.05, p < 0.05; GPR37L1: 0.85 ± 0.08 vs. 1.05 ± 0.02, p < 0.05; Figure 10h) and 12 weeks (GPR37: 1.00 ± 0.03 vs. 1.17 ± 0.07, p < 0.05; GPR37L1: 1.06 ± 0.19 vs. 1.28 ± 0.06, p < 0.05; Figure 10h).

Associating MAPK and PS in SH-SY5Y cells

To gain further insight into the connection between p-ERK and PS, the specific MEK1/2 inhibitors U0126 and PS18 were used in in vitro experiments. SH-SY5Y neuroblastoma cells were exposed to different concentrations of U0126 (1–10 μM) for 30 min to optimize the experimental conditions. U0126 at 10 μM selectively inhibited p-ERK1/2 (Figure 11a). In a previous study [4], the addition of 300 ng/mL PS18 to SH-SY5Y cells did not exhibit significant toxic effects. Thus these concentrations were used to evaluate whether ERK activation was related to PS expression. Cells were pretreated with 10 μM U0126 for 30 min prior to adding PS18. After culturing in the presence of PS18 or DMEM for 6, 12, 18, or 24 h, cells were collected and analyzed by Western blot. Interestingly, pretreatment with U0126 markedly suppressed PS expression and its receptors, GPR37 and GPR37L1 (p < 0.01, Figure 11b, e-g). However, after treatment with PS18, these levels increased to different degrees after 6–24 h (p < 0.05, Figure 11d-g). In addition, the levels of p-ERK1/2 in SH-SY5Y cells were stimulated with PS18, peaking 6 h after treatment (Figure 11c-d). These results demonstrate that ERK1/2 activity is positively correlated with PS activity, and PS18 activates p-ERK1/2 in SH-SY5Y cells.

Discussion

The data presented here provide a comprehensive picture of the distribution of PS in the mouse brain. The spatio-temporal expression of PS differed between mdx and C57BL/10 mice, indicating that DMD is not only related to muscles but also to the CNS in mdx mice.

In human DMD, muscle weakness begins at age 3–4 years. This muscle weakness is due to irreversible, progressive loss of skeletal muscle and results in the need for a wheelchair at age 10 years and death at 20 years. The pathology of the mdx mouse is characterised by histologically well-defined stages with similarity to the human pathology. Necrotic or apoptotic processes in combination with inflammation emerge at approximately 3 weeks of age [23]. Regeneration processes are initiated around the age of 6 weeks and continue, together with ongoing degeneration, until 12 weeks of age [31-34]. PS levels in mdx-affected muscle decreases at these ages [7]. Thus, in our study, we used mdx mice aged 4 and 12 weeks.

Patients with DMD display a variable degree of cognitive impairment, ranging from mild deficits in verbal skills, selective attention and poor memory performance to mental retardation [19,35,36]. Genetic loss of dystrophin has long been suggested to be responsible for some of these deficits, as dystrophin is normally expressed in brain structures involved in diverse cognitive functions, such as the hippocampus, neocortex and cerebellum [25,37], areas where PS is abundant.

PS potently facilitates regeneration in ischemic hippocampal neurons and transected sciatic nerves [38,39]. In vivo studies showed that PS and PS-derived peptides prevent ischemia-induced hippocampal neuronal death and ameliorate subsequent learning disabilities [40,41]. PS-derived peptides also prevented neuronal loss in MPTP-induced Parkinson’s disease [4,42]. In the present study, PS was expressed in neurons in mdx and C57BL/10 mice but showed reduced levels of expression in many brain regions, suggesting that PS may be related to some pathological changes in the brains of mdx mice.

Dystrophin and its autosomal homolog utrophin (Utrn) form the DAPC, which effectively forms transmembrane links...
between the extracellular matrix and the cytoskeleton [43,44]. The amino and carboxy termini of Utrn and dystrophin share considerable amino acid sequence homology with actin- and dystroglycan-binding domains [45,46]. DAP reduction is associated with alterations of the blood-brain barrier (BBB) [47,48] during development of the dystrophic mdx mouse. PS is present in CSF and neuronal tissues and prevents apoptosis of neuronal cells [38,40,49,50]. Western blot and immunohistochemistry demonstrated that PS levels decreased in the mdx brain. A lack of dystrophin may induce neuronal and/or BBB damage and may be related to PS expression, while the decreased level of PS may affect neuronal function.

Secretory-type PS mRNA (Figure 9e-h) in the choroid plexus and PS protein in both the choroid plexus (Figure 9a-d, i) and CSF (Figure 9l) were detected in mdx and C57BL/10 mice. In both juvenile and adult mice, mRNA and protein expression were decreased in the choroid plexus of mdx mice, but protein levels in CSF were similar. This discrepancy may be explained by the low level of PS receptors in the brain (Figure 10), whereas PS in the CSF is normal (Figure 9l-m) regardless of low PS production in the choroid plexus (Figure 9j-k).

The highest levels of exon 8-containing PS mRNA were detected in the brain, heart and skeletal muscle [51-55]. Exon 8-containing PS mRNA is translated to unprocessed PS, which is more efficiently secreted, whereas PS mRNA without exon 8 is translated to the PS precursor of the four lysosomal saposins. Several studies have demonstrated a sharp decline in the exon 8-containing PS isoform in the rat brain following ischemia and stab wounds [53]. In our study, cRNA probes recognising total PS (AS1), secretory-type (AS3) or lysosome-type PS (AS4) allowed us to show the cellular localisation of PS mRNA isoforms in defined areas of the brain. Based on in situ hybridization data, we detected prominent expression of Pro+9 mRNA in juvenile and adult brain tissues, suggesting that exon 8-containing secretory-type PS is expressed in these neurons. At the same time, we found that full-length PS is also expressed in brain regions. Furthermore, we showed that PS-positive cell numbers decreased in juvenile and adult mdx mouse brains. Recent research showed that the expression level of exon 8-containing PS mRNA in mice reaches a peak after birth, when synaptogenesis is extensive [51]. Changes in synaptic transmission have been well documented to be associated with neurotoxicity after nerve injury [56,57]. In DMD, the cognitive impairment in the nervous system may be associated with the decrease in PS levels.

GPR37 and GPR37L1 are orphan G protein coupled receptors, almost exclusively expressed in the nervous system [30], for the neuroprotective and glioprotective factors prosaptide and PS. Prosaptide stimulation of cells transfected with GPR37 or GPR37L1 induces the phosphorylation of ERK. As demonstrated by our data, when the activation of ERK was inhibited by U0126, expression of PS and these receptors was inhibited (Figure 11e-g), and PS18 stimulated ERK phosphorylation (Figure 11c-d) in SH-SY5Y cells. However, interestingly, in the brains of mdx mice, the expressions of PS and its receptors (Figure 10) were decreased despite an increase in ERK (Figures 7, 8). This indicates that regulation of the ERK pathway is complex in the brains of mdx mice.

The MAPK family is an important mediator of signal transduction processes that coordinate the cellular response to a variety of extracellular stimuli. Three major mammalian MAPK subfamilies have been described: ERK, the c-Jun N-
terminal kinases (JNK, also called stress-activated protein kinase), and the p38 kinases. Each MAPK is activated through a specific phosphorylation cascade. ERK activation controls various cell responses, such as proliferation, migration, differentiation and death [58]. Many studies have supported the general view that activation of the ERK pathway delivers a survival signal [28] and our in vitro experiment demonstrated that PS18 activated p-ERK1/2 in SH-SY5Y cells. This is similar to what happens when PS and prosaptides (peptides encompassing the neurotrophic region of PS) bind to a putative G protein-coupled receptor [59] and activate ERK [27]. Interestingly, in our in vivo study, there were no changed in JNK and p38 expression but increased in ERK1/2 expression in the brains of mdx mice (Figures 7, 8, 9h). Activation of ERK1/2 has been demonstrated in mdx-affected skeletal muscle [60]. Furthermore, ERK activity can promote either intrinsic or extrinsic apoptotic pathways by inducing mitochondrial cytochrome c release or caspase-8 activation, permanent cell cycle arrest, and/or autophagic vacuolization [61]. ERK activity has been clearly implicated in neurodegenerative diseases and brain injury following ischemia/reperfusion in rodents [62-64]. The Ras/Raf/ERK pathway plays a critical role in promoting several forms of cell death in response to various stress stimuli in vitro and in vivo. From these reports and our studies, we speculate that activated ERK may contribute to apoptosis in the brains of mdx mice and further decrease the expression of PS and its receptors. The precise mechanisms responsible for these findings should be investigated in further studies.

In summary, PS expression was lower in the brains of mdx mice, indicating that PS is associated with dystrophin deficiency. However, the mechanisms underlying dystrophin deficiency and these decreased PS levels remain to be determined. Further work may be focused on ERK phosphorylation and apoptosis in mdx mice, and the neuroprotective actions of PS and prosaptide mediated by GPR37 and GPR37L1 that may provide new therapeutic possibilities for the treatment of DMD.

**Materials and Methods**

**Animals**

Male mdx mice (C57BL/10-mdx; Clea Japan Inc., Tokyo, Japan) aged 4 or 12 weeks and C57BL/10 (Clea Japan Inc., Tokyo, Japan) of the corresponding ages were used in this study. All animals were housed at a constant temperature (22°C) under a 12/12 h light/dark cycle and given food and water ad libitum. This study was carried out in strict accordance with the recommendations in the Guidelines of the Animal Care Committee of Ehime University. The protocol was approved by the Animal Care Committee of Ehime University (Permit Number: 05A261). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

**Prosaposin Antibody and 18-mer peptide**

Medical and Biological Laboratories Co., Ltd (Nagoya, Japan) performed all of the procedures to create the PS-specific antibody (PS-Ab). Analysis of the amino acid sequence of rat PS (M19936 [65]; showed that an antibody specific for PS could be generated by immunising rabbits with a synthetic oligopeptide corresponding to 409-PKEPAPPKQPEEPKQSLARHAVPPQK-434, a portion of PS that undergoes proteolysis to generate four saposins. This amino acid sequence does not encode any saposin, and the analysis included protein secondary structure predictions and analyses of accessibility to solvents, flexibility, surface probability, antigenicity and hydrophilicity, as well as dipole analyses. The analytical method involved 150 g of conjugate in 500 L of phosphate-buffered saline (PBS), emulsified with complete Freund’s adjuvant and injected subcutaneously into a rabbit. Five booster immunisations of emulsions in incomplete Freund’s adjuvant followed at 4–8-week intervals. The rabbit was killed and bled 10 days after the final injection. The antiseraum was affinity-purified with the oligopeptide. The PS-Ab titre in the serum was 1:10 000 in Western blot analyses. The species reactivity was also confirmed in mice by Western blotting. An 18-mer peptide (PS18: LSELIINNATEELLIKGL) comprising the hydrophilic sequence of rat saposin C was synthesized by Operon Technology (Tokyo, Japan).

**Cerebrospinal fluid withdrawal**

Cerebrospinal fluid (CSF) samples are taken from the cisterna magna using a method that was published previously [66]. In brief, the mouse was euthanized then placed prone on the stereotaxic instrument and the head was secured with the head adaptors, the posterior neck muscles were removed with a surgical blade and a glass capillary tube with the inner diameter of about 0.5 mm (Borosilicate glass, B100-75-10, The Sutter Instrument Inc) was inserted through the arachnoid membrane into the cisterna magna. CSF was aspirated by capillary forces. Repeated specimens (obtained in three to four suction from the same opening) were examined for the visible presence of blood by comparing small CSF sample in the pipette to a brightly lit white background. Any discrepancy between pipette colour and white surface was used as a criterion to discard the last specimen and terminate sampling. Approximate 10–20 µl of clean CSF was obtained from each mouse. CSF was collected in 500 µl tubes and subsequently stored at -80°C until use.

**Immunohistochemical staining for PS**

Three mice in each group were transcardially perfused with saline, followed by 4% paraformaldehyde. Their forebrains and cerebellums were dissected and immersed in the same fixative at 4°C. The samples were then dehydrated and embedded in paraffin. Serial 7-µm coronal sections were cut using a microtome. The routine avidin-biotin complex (ABC) method was used to detect the distribution of PS in the rat hippocampus and cortex. Briefly, sections were dewaxed, rehydrated and treated with 0.1 M PBS containing 10% methanol and 3% hydrogen peroxide (H2O2) for 10 min. After rinsing with PBS, the sections were treated with 5% bovine serum albumin (BSA), 1% normal swine serum (NSS) and 1% normal goat serum (NGS) in PBS for 1 h and then incubated overnight with rabbit anti-PS (1:100) at 4°C. After rinsing, the
sections were incubated in biotinylated goat anti-rabbit IgG (1:500) for 2 h at room temperature. After rinsing, the avidin–biotin–peroxidase complex (1:300; Dako, Glostrup, Denmark) was applied for 1 h at room temperature. The sections were immersed in 3,3-diaminobenzidine (Sigma, St. Louis, MO, USA) with 0.0033% H2O2 for about 10 min. After rinsing with distilled water, the sections were mounted and examined under a light microscope. As a negative control, some sections were incubated with normal rabbit serum (1:100) instead of the primary antibody and processed as described above. Nonspecific staining was not observed.

Western blotting

Three mice were euthanised by intraperitoneal injection of an overdose of sodium pentobarbital. The cerebral cortex, hippocampus, cerebellum and choroid plexus were dissected. Briefly, the tissues were homogenised 1.5 (w/v) in ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.25% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), protease inhibitor cocktail and phosphatase inhibitor cocktail (both 1:100; Nacalai Tesque, Kyoto, Japan). The resulting homogenates were centrifuged (12 000 × g, 30 min, 4°C). The supernatants were collected, and total protein levels were determined using a BCA protein assay kit (Pierce, Rockford, IL, USA). CSF was withdrawn by the periventricular method. Proteins (15 μg) and 2μl undiluted CSF in LDS sample buffer were separated on 12% SDS polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) membranes in a wet transfer device (30 V, 1 h). Membranes were preincubated in 5% BSA for 2 h and then incubated overnight at 4°C with the following primary antibodies: rabbit anti-PS-Ab (1:500), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204; 1:500; Enogene Biotech, New York, NY, USA), rabbit anti-ERK1/2 (1:500; Enogene Biotech), rabbit anti-phospho-p38 (Tyr182; 1:500; Enogene Biotech), rabbit anti-p38 (1:500; Enogene Biotech), rabbit anti-phospho-SAPK/c-Jun N-terminal kinase (JNK; 1:1000 Thr183/Tyr185, 9251; Cell Signaling Technology, Danvers, MA, USA), rabbit anti-SAPK/JNK (1:1000, 9252; Cell Signaling Technology), Rabbit anti-GPR37 (1:500; Enogene Technology, Taipei, Taiwan) and rabbit anti-GPR37L1 (1:1000, Abnova Technology) and a mouse anti-GAPDH polyclonal antibody (1:1000; Imgenex, San Diego, CA, USA). Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies (1:5000; KPL, Gaithersburg, MD, USA) against rabbit or mouse for 1 h. After washing, the membranes were reacted with reagents from an enhanced chemiluminescence (ECL) kit (New England Lab, Woburn, MA, USA). Finally, specific protein bands were visualised by exposing the membranes to film (FujiFilm, Tokyo, Japan). After development, the intensities of protein bands were quantified using ImageJ software (NIH, Bethesda, MD, USA).

In situ hybridization

In situ hybridization was performed to detect PS mRNA as previously described [67-69]. Briefly, six mice aged 4 weeks in each group were killed by decapitation. Forebrains and cerebellums were immediately dissected, frozen in dry ice and stored at -80°C. Sections (20 μm thick) were cut on a cryostat, thaw-mounted onto silane-coated slides and stored at -80°C until use.

Three antisense 36-mer oligonucleotide probes, AS1, AS3 and AS4, and one sense probe, SS1 (used for control), were synthesised commercially (Operon Biotechnologies, Inc., Tokyo, Japan). AS1 was complementary to bases 1704–1739 in the 3′-untranslated region of the PS cDNA, permitting the detection of both Pro+9 mRNA and Pro+0 mRNA (total PS mRNA). AS3 was synthesised to detect Pro+9 mRNA (exon 8-containing PS mRNA), as the sequence of the PS cDNA determined by Collard et al. [65] does not contain the 9-base insertion after base 801 of the PS cDNA [53] and thus only detects Pro+9 mRNA. In contrast, AS4 was complementary to bases 778–813 of the PS cDNA, which excludes the 9-base insertion, and thus detects Pro+0 mRNA (exon 8-excluded PS mRNA). The sense probe SS1, complementary to AS1, was used as a control. The sequences of the four probes were as follows:

SS1: 5′- GCAGAAAGTCGCTACTTGTGGTCTAGGGTAATGAA-3′ (negative control)

AS1: 5′- TTCACTACCTAGACCCCAACAGTAGGCGACTTCTGC-3′ (Pro+0 and Pro+9)

AS3: 5′- CTTGGGTTGCTATCTCGATCTGACCATCATCATCTCG-3′ (Pro+9)

AS4: 5′- TCCCTTGCGTGCATGTGACCATCATCATCTGGACGC-3′ (Pro+0)

The sequence in italics (AS3) is complementary to the 9-base insertion. The underlined sequences in AS1 and AS4 are the shared sequences. The probes were labelled with [35S]dATP (46.2Tbq/mmol; PerkinElmer Life Sciences, Boston, MA, USA) using terminal deoxynucleotidyl transferase (Takara, Tokyo, Japan), and a specific activity of approximately 1.0 × 10^7 dpm/ml was obtained.

Sections were fixed in 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) for 15 min, rinsed in 4× standard saline citrate (SSC, pH 7.4) and dehydrated through a graded ethanol series. Sections were then hybridised with [35S]-labelled probes in hybridization buffer (50% denionised formamide, 1% Denhardt's solution, 250 μg/ml yeast total RNA, 0.1 g/ml dextran sulphate, 0.12 M PB and 20 mM DTT in 4× SSC) at 41°C overnight. After hybridization, sections were rinsed three times in 1× SSC at 55°C for 20 min, dehydrated through a graded ethanol series, coated with Kodak NBT-2 emulsion (Eastman Kodak, Rochester, NY, USA) and exposed at 4°C for 4 weeks. Finally, the sections were developed in a D-19 developer (Eastman Kodak). After dehydration and mounting, the sections were observed under a microscope.

The grey intensity was examined under an Eclipse E-800M microscope (Nikon, Tokyo, Japan) coupled to a Pro-Series High Performance CCD camera (Sony, Tokyo, Japan). Scanning was performed at 400× magnification to measure the average intensity. For quantification, 10 sections per animal
were analyzed and the optical density (OD) was calculated conventionally: OD = \[\log_{10} \text{(incident light/transmitted light)}\]. The grey intensity was analyzed using ImageJ.

Human SH-SY5Y neuroblastoma cells culture and treatment

Human SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s minimum essential medium (DMEM; Wako, Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS; PAA Laboratories, Yeovil, Somerset, UK), 100 U/mL penicillin, and 100 U/mL streptomycin at a pH of 7.4. Culture medium was changed every 3–4 days, and cells were maintained in a humidified 5% CO2 atmosphere at 37°C and sub-cultured at a ratio of 1:20 every 7–10 days. Culture medium was changed to DMEM without FBS for 12 h before the start of each experiment. All experiments were performed using 70–80% confluent cultures. 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126, #9903, Cell Signaling Technology) was used to inhibit p44 and p42 MAP kinase activities. U0126 (5 mg) was resuspended in 1.31 mL DMSO to prepare a 10 mM stock. PS18 (25 µg/mL) was dissolved in 0.01 M phosphate-buffered saline (PBS) and filtered with a 0.22-µm-filter membrane (Millipore, Billerica, MA, USA).

Different concentrations of U0126 and 300 ng/mL PS18 were diluted in SH-SY5Y medium and used immediately.

Statistics

All values are expressed as the mean ± standard deviation (SD), and all statistical analyses were carried out using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Data were subjected to analysis of variance (ANOVA) followed by Fisher’s post hoc test. A p-value of < 0.05 was considered significant.

Acknowledgements

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/jxG0n5.

Author Contributions

Conceived and designed the experiments: HLG HN SM. Performed the experiments: HLG CL HN. Analyzed the data: HLG CL HN TS SM. Contributed reagents/materials/analysis tools: TS NK SS ZW YC SM. Wrote the manuscript: HLG HN SM.

References

1. Kondoh K, Sano A, Kakimoto Y, Matsuda S, Sakanaka M (1993) Distribution of prosaposin-like immunoreactivity in rat brain. J Comp Neurol 334: 590-602. doi: 10.1002/cne.903340407. PubMed: 8408767.
2. Sano A, Hineno T, Mizuno T, Kondoh K, Ueno S et al. (1989) Sphingolipid hydrolase activator proteins and their precursors. Biochem Biophys Res Commun 165: 1191-1197. doi: 10.1016/0006-291X(89)92728-9. PubMed: 2615086.
3. Hosoda Y, Miyawaki K, Saito S, Chen J, Bing X et al. (2007) Distribution of prosaposin in the rat nervous system. Cell Tissue Res 330: 197-207. doi:10.1007/s00441-007-0446-9. PubMed: 17763872.
4. Gao HL, Li C, Nabecka H, Shimokawa T, Saito S et al. (2013) Attenuation of MPTP/MPP(+) toxicity in vivo and in vitro by an 18-mer sulfatide activator protein. Alternative splicing that generates three mRNA products and a newly found mutation responsible for a clinical disease. J Biol Chem 287: 8955-8960. doi: 10.1074/jbc.M112.407765. PubMed: 24000362.
5. Kishimoto Y, Hiraika M, O'Brien JS (1992) Saposins: structure, function, distribution, and molecular genetics. J Lipid Res 33: 1255-1267. PubMed: 2615086.
6. Kondoh K, Hineno T, Sano A, Kakimoto Y (1991) Isolation and characterization of prosaposin from human milk. Biochem Biophys Res Commun 181: 286-292. doi:10.1016/S0006-291X(05)81415-9. PubMed: 1958198.
7. Li C, Gao HL, Shimokawa T, Nabecka H, Hamada F et al. (2013) Prosaposin expression in the regenerated muscles of mdx and cardiotoxin-treated mice. Histo Histopathol 28: 875–92. PubMed: 23325523.
8. Hineno T, Sano A, Kondoh K, Ueno S, Kakimoto Y et al. (1991) Secretion of sphingolipid hydrolase activator precursor, prosaposin, Biochem Biophys Res Commun 176: 668-674. doi:10.1016/0006-291X(91)90145-9. PubMed: 1958198.
9. Hollt Schmidt H, Sandhoff K, Kwon HY, Harzer K, Nakano T et al. (1991) Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J Biol Chem 266: 7560-7566. PubMed: 2019586.
10. Kreda SM, Fujita N, Suzuki K (1994) Expression of sphingolipid activator protein gene in brain and systemic organs of developing mice. Dev Neurosci 16: 90-99. doi:10.1159/000112093. PubMed: 7967522.
11. Sun Y, Witte DP, Grabowski GA (1994) Developmental and tissue-specific expression of prosaposin mRNA in murine tissues. Am J Pathol 145: 1390-1398. PubMed: 7992842.
12. O'Brien JS, Carson GS, Seo HC, Hiraika M, Kishimoto Y (1994) Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci U S A 91: 9593-9596. doi:10.1073/pnas.91.20.9593. PubMed: 7594231.
13. Sikora J, Harzer K, Ellender M (2007) Neurolyosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin. Acta Neuropathol 113: 163-175. doi:10.1007/s00401-006-0148-7. PubMed: 17024494.
14. O'Brien JS, Carson GS, Seo HC, Hiraika M, Weiler S et al. (1995) Identification of the neurotrophic factor sequence of prosaposin. FASEB J 9: 681-685. PubMed: 7768361.
15. Qi X, Qin W, Sun Y, Kondoh K, Grabowski GA (1996) Functional organization of saposin C. Definition of the neurotrophic and alpha-glucoisidase activation regions. J Biol Chem 271: 8874-8880. doi:10.1074/jbc.271.12.8874. PubMed: 8636113.
16. Hoffman EP, Brown RH Jr., Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928. doi:10.1016/0092-8674(87)90579-4. PubMed: 3319190.
17. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517. doi: 10.1016/0092-8674(87)90504-4. PubMed: 3607877.
18. Emery AE (1991) Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disorders 1: 19-29. doi:10.1016/0960-8966(91)90039-U. PubMed: 1822774.
19. Anderson JL, Head SL, Rae C, Morley JW (2002) Brain function in Duchenne muscular dystrophy. Brain 125: 4-13. doi: 10.1093/brain/awf012. PubMed: 11934588.
20. Bresolin N, Castelli E, Comi GP, Felisari G, Bardoni A et al. (1994) Cognitive impairment in Duchenne muscular dystrophy. Neuromuscul Disord 4: 359-369. doi:10.1016/0960-8966(94)90072-8. PubMed: 7981593.
21. Sekiguchi M, Zushida K, Yoshida M, Maekawa M, Kanichi S et al. (2009) A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132: 124-135. doi:10.1093/brain/awp040. PubMed: 19927146.
22. Wickens RK, Kihlgren M, Melin L, Eeg-Olofsson O (2004) Specific cognitive deficits are common in children with Duchenne muscular dystrophy. Dev Med Child Neurol 46: 154-159. PubMed: 14995084.
23. Buffell G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81: 1189-1192. doi:10.1073/pnas.81.4.1189. PubMed: 6983703.
Prosaposin Expression in mdx Mouse Brain

24. Lidov HG (1996) Dystrophin in the nervous system. Brain Pathol 6: 63-77. doi:10.1111/j.1608-1811.1996.tb00683.x. PubMed: 8667748.

25. Lidov HG, Byers TJ, Kunkel LM (1993) The distribution of dystrophin in the murine central nervous system: an immunocytochemical study. Neuroscience 54: 167-178. doi:10.1016/0306-4522(93)90392-9. PubMed: 8518441.

26. Lidov HG, Byers TJ, Watkins SC, Kunkel LM (1990) Localization of dystrophin to post synaptic regions of central nervous system cortical neurons. Nature 348: 725-728. doi:10.1038/348725a0. PubMed: 2259381.

27. Campana WM, Hiraia M, O'Brien JS (1998) Prosapotide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 12: 307-314. PubMed: 9506474.

28. Misasi R, Sorice M, Di Marzo L, Campana WM, Molinari S et al. (2001) Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase. FASEB J 15: 467-474. doi:10.1096/fj.00-0217com. PubMed: 1156962.

29. Hiraia M, Yamauchi T, Tsuji S, Nishizawa M, Miyatake T et al. (1993) Activation of human lysosomal sialidase. J Biochem 114: 901-905. PubMed: 8138549.

30. Meyer RC, Giddens MM, Schaefer SA, Hall RA (2013) GPR37 and GPR137L1 are receptors for the neuroprotective and glycospingolipid binding factors prosaposin and prosapotide. Proc Natl Acad Sci U S A 110: 9529-9534. doi:10.1073/pnas.1219004110. PubMed: 2369054.

31. Anderson JE, Ovalle WK, Bressler BH (1987) Electron microscopy and autoradiographic characterization of hindlimb muscle regeneration in the mdx mouse. Anat Rec 219: 243-257. doi:10.1002/ar.192919005. PubMed: 3242943.

32. Dangain J, Vrbova G (1984) Muscle development in mdx mutant mice. Muscle Nerve 7: 700-704. doi:10.1016/0148-6916(84)90055-8. PubMed: 6543918.

33. DiMarco JX, Uzman A, Strohmaier RC (1991) Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev Biol 148: 314-321. doi:10.1016/0012-1606(91)90340-9. PubMed: 1936658.

34. Turk R, Sternberg E, de Meijer EJ, van Ommen GJ, den Dunnen JT (1994) Conservation of expression and alternative splicing in the prosaposin (SGP-1) gene reveals the presence of an exon that is alternatively spliced in human brain. J Neurochem 66: 2197-2200. doi:10.1002/jnc.2620660547. PubMed: 8780053.

35. Conserved expression and alternative splicing in the prosaposin gene reveals the presence of an exon that is alternatively spliced in transcribed mRNAs. Mol Reprod Dev 48: 1-8. doi:10.1002/mrd.1097480101. PubMed: 9267575.

36. Cohen T, Auerbach W, Raviv L, Bodennec J, Fein A et al. (2005) The exon 8-containing prosaposin splice variant is dispensable for mouse development, lysosomal function, and secretion. Mol Cell Biol 25: 2431-2440. doi:10.1128/MCB.25.6.2431-2440.2005. PubMed: 15743835.

37. Morita F, Wen TC, Tanaka J, Hata R, Desaki J et al. (2001) Protective effect of a prosaposin-derived, 18-mer peptide on slowly progressive neurological degeneration after brief ischemia. J Cereb Blood Flow Metab 21: 1295-1302. PubMed: 11702044.

38. Misasi R, Sorice M, Di Marzo L, Campana WM, Molinari S et al. (2001) Prosaposin (SGP-1) gene reveals the presence of an exon that is alternatively spliced in transcribed mRNAs. Mol Reprod Dev 48: 1-8. doi:10.1002/mrd.1097480101. PubMed: 9267575.

39. Cohen T, Auerbach W, Raviv L, Bodennec J, Fein A et al. (2005) The exon 8-containing prosaposin splice variant is dispensable for mouse development, lysosomal function, and secretion. Mol Cell Biol 25: 2431-2440. doi:10.1128/MCB.25.6.2431-2440.2005. PubMed: 15743835.

40. Arundine M, Tymianski M (2004) Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 61: 657-688. doi:10.1007/s00018-003-3319-x. PubMed: 15052405.

41. Huetten JER (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70: 387-407. doi:10.1016/S0301-0082(01)00122-9. PubMed: 14511698.

42. Murphy LO, Blenis J (2006) MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31: 268-275. doi:10.1016/j.tibs.2006.03.009. PubMed: 16603362.

43. Hiraia M, Campana WM, Martin BM, O'Brien JS (1997) Prosaposin receptor: evidence for a G-protein-associated receptor. Biochem Biophys Res Commun 240: 415-418. doi:10.1006/bbrc.1997.7673. PubMed: 9384989.

44. Hnia K, Hugon G, Ravier F, Masmoudi A, Mercier J et al. (2007) Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophic-mdx Mice. Am J Pathol 170: 633-643. doi:10.2353/ajpath.2007.060344. PubMed: 17253531.

45. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J et al. (1992) Primary structure of dystrophin-related protein. Nature 350: 591-593. doi:10.1038/360591a0. PubMed: 1461283.

46. Tinsley JM, Davies KE (1996) Expression of the dystrophin gene in mouse and rat brain. Neuroreport 7: 67-73. doi:10.1097/00001756-199602070-00010. PubMed: 8667748.
by rat Sertoli cells: sequence similarity with the 70-kilodalton precursor to sulfatide/GM1 activator. Biochemistry 27: 4557-4564. doi:10.1021/bi00412a050. PubMed: 3048385.
66. Liu L, Duff K (2008) A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp.
67. Chen J, Saito S, Kobayashi N, Sato K, Terashita T et al. (2008) Expression patterns in alternative splicing forms of prosaposin mRNA in the rat facial nerve nucleus after facial nerve transection. Neurosci Res 60: 82-94. doi:10.1016/j.neures.2007.09.010. PubMed: 18022721.
68. Terashita T, Saito S, Miyawaki K, Hyodo M, Kobayashi N et al. (2007) Localization of prosaposin in rat cochlea. Neurosci Res 57: 372-378. doi:10.1016/j.neures.2006.11.006. PubMed: 17156877.
69. Unuma K, Chen J, Saito S, Kobayashi N, Sato K et al. (2005) Changes in expression of prosaposin in the rat facial nerve nucleus after facial nerve transection. Neurosci Res 52: 220-227. doi:10.1016/j.neures.2005.03.009. PubMed: 15927723.